Skip to main content

Table 5 Cost effectiveness analysis over 2-year treatment duration

From: The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia

Therapy

Cost/patient (US$)

QALYs gained/patient

ICER (ΔC/ΔE)

Comparator

Ibuprofen + PPI

4,204.10

1.11

3,787.48

No treatment

Celecoxib + PPI

4,512.80

1.37

1,187.31

Ibuprofen + PPI

Celecoxib*

4,716.80

1.24

Dominated

-

Diclofenac + PPI*

4,891.60

1.17

Dominated

-

Ibuprofen*

5,575.10

0.85

Dominated

-

Diclofenac*

5,662.50

0.96

Dominated

-

Etoricoxib + PPI

5,892.40

1.35

Dominated

-

Etoricoxib

6,621.80

1.23

Dominated

-

  1. *Simple dominance: Another option is less expensive and more effective
  2. ICER, incremental cost-effectiveness ratio; PPI, proton-pump inhibitor; QALY, quality-adjusted life year
  3. ICER: additional cost per patient achieving a unit of effectiveness compared with the next less costly, non-dominated option
Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us